Due Diligence Guide · IV Therapy Clinic

Due Diligence Guide for Acquiring an IV Therapy Clinic

A phase-by-phase framework covering medical compliance, revenue quality, and clinical risk for buyers targeting cash-pay IV hydration businesses in the lower middle market.

Find IV Therapy Clinic Acquisition Targets

IV therapy clinics operate at the intersection of healthcare and lifestyle, creating unique due diligence demands. Buyers must validate medical director transferability, state-specific corporate practice of medicine compliance, compounding pharmacy relationships, and membership revenue retention before committing capital. This guide structures that process into three phases.

IV Therapy Clinic Due Diligence Phases

01

Phase 1: Legal and Regulatory Review

Confirm the clinic operates within state medical supervision laws and that all licenses, permits, and clinical agreements survive ownership transfer without triggering compliance violations.

Medical Director Agreement Transferabilitycritical

Verify the medical director agreement is assignable to a new owner and the supervising physician is willing to remain post-close under a restructured, arms-length contract.

Corporate Practice of Medicine Compliancecritical

Engage a healthcare attorney to confirm the clinic's ownership and supervision structure complies with state-specific CPOM laws, which vary significantly across jurisdictions.

State Licensing and Health Department Permitscritical

Audit all active clinic certificates, health department permits, and nurse licenses for currency, any violations, or conditions that could restrict operations post-acquisition.

02

Phase 2: Financial and Revenue Quality Analysis

Validate revenue sustainability by examining membership retention, visit frequency trends, customer concentration, and the accuracy of reported EBITDA against actual cash-pay collections.

Membership Program Retention and Churncritical

Request month-over-month active member counts, churn rates, and average membership tenure for the past 24 months to assess recurring revenue stability and predictability.

Revenue Concentration and Walk-In Dependencyimportant

Identify whether more than 20% of revenue derives from a single client, employer wellness contract, or seasonal event to assess transferability risk and revenue durability.

Average Revenue Per Visit Trendsimportant

Analyze service mix and ticket size trends over 36 months to determine whether NAD+, peptide, or premium add-on adoption is growing or declining relative to basic hydration visits.

03

Phase 3: Clinical and Operational Risk Assessment

Evaluate malpractice exposure, compounding pharmacy compliance, staff licensing, and documented clinical protocols to quantify liability and operational continuity risk.

Malpractice and State Board Historycritical

Obtain a full malpractice claims history, request state nursing and medical board complaint records, and confirm current professional liability insurance coverage limits for all providers.

Compounding Pharmacy Agreements and FDA Compliancecritical

Review all compounding pharmacy supplier contracts for 503B accreditation status and confirm IV formulations for NAD+, glutathione, and high-dose vitamins meet current FDA guidance.

Clinical Protocol Documentation and Staff Licensingimportant

Confirm written SOPs exist for all infusion protocols, adverse event response, and patient intake, and verify every administering nurse holds a current, unrestricted state RN or LPN license.

IV Therapy Clinic-Specific Due Diligence Items

  • Confirm the medical director's non-compete or exclusivity clause does not prohibit them from serving the clinic post-acquisition under a new ownership entity.
  • Validate that all compounding pharmacy relationships include written supply agreements with assignability clauses and no dependency on a single non-accredited 503A compounder.
  • Request a full export of the customer database including visit history, lifetime value, and membership status to independently verify POS-reported revenue and retention metrics.
  • Assess mobile IV unit operations separately if applicable, including vehicle titling, liability insurance, and whether mobile services are permitted under the clinic's state licensure.
  • Review online reputation metrics including Google review volume and rating trends, as 4.8+ star profiles with 200+ reviews represent a material intangible asset with direct impact on valuation.

Frequently Asked Questions

What is the biggest risk when acquiring an IV therapy clinic?

Medical director dependency is the highest risk. If the owner serves as the sole supervising physician with no replacement identified, regulatory operations could collapse immediately post-close.

Are IV therapy clinics eligible for SBA 7(a) financing?

Yes, most IV therapy clinics qualify for SBA 7(a) loans covering 75–90% of the purchase price, provided the clinic has clean financials and the medical director agreement is transferable to the new owner.

What EBITDA multiple should I expect to pay for an IV therapy clinic?

Established clinics with membership programs and transferable medical director agreements typically trade at 3x–5.5x EBITDA, with premium multiples for multi-location operators or strong recurring revenue documentation.

How do I evaluate the quality of a membership program during due diligence?

Request 24 months of month-over-month active member counts, average revenue per member, and churn rates. Healthy programs show sub-10% monthly churn and 200+ active members generating predictable baseline revenue.

More IV Therapy Clinic Guides

Find IV Therapy Clinic businesses ready for acquisition

DealFlow OS surfaces targets with seller signals and motivation scores — so you know before you start diligence. Free to join.

Start finding deals — free

No credit card required